Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer

Gene Therapy

Volumn 4, Issue 6, 1997, Pages 600-610

  Forestall, S P ^a   Dando, J S ^a,b   Chen, J ^a   De Vries, P ^a,c   Bohnlein E ^a   Rigg, R J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Gene Therapy Program   (Italy)

^c Cell Therapeutics   (United States)

Author keywords

Hematopoietic cell transduction; Retroviral packaging cell lines; Tropism; Vector production

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; VIRUS VECTOR;

ARTICLE; BIOREACTOR; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SUPERNATANT; VIRUS CELL INTERACTION; VIRUS REPLICATION; XENOTROPIC VIRUS;

ALOCASIA MACRORRHIZOS; GIBBON APE LEUKEMIA VIRUS; HYLOBATES SP.; MURINAE; MURINE LEUKEMIA VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030855730     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300420     Document Type: Article

References (53)

1. Kantoff PW et al. Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J Exp Med 1987; 166: 219-234.
2. Miller AD. Progress towards human gene therapy. Blood 1990; 76: 271-278.
3. Xu LC et al. Poor transduction efficiency of human hematopoietic progenitor cells by a high-titer retrovirus producer cell clone. J Virol 1994; 68: 7634-7636.
4. von Kalle C et al. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 1994; 84: 2890-2897.
5. Bunnell BA et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7739-7743.
6. Sommerfelt MA, Weiss RA. Receptor interference groups of 20 retroviruses plating on human cells. Virology 1990; 176: 58-69.
7. Weiss RA, Tailor CS. Retrovirus receptors. Cell 1995; 82: 531-533.
8. Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
9. Miller AD, Chen F. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 1996; 70: 5564-5571.
10. Adams RM et al. Transduction of primary hepatocytes with amphotropic and xenotropic retroviral vectors. Proc Natl Acad Sci USA 1992; 89: 8981-8985.
11. Garcia JV, Jones C, Miller AD. Localization of the amphotropic murine leukemia virus receptor gene to the pericentromeric region of human chromosome 8. J Virol 1991; 65: 6316-6319.
12. Porter CD et al. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther 1996; 7: 913-919.
13. Charreau B, Grepinet O, Delouis C, Nandi PK. Establishment of porcine cell lines producing a murine recombinant retrovirus in order to transfer the nlslacZ gene into porcine cells. Res Virol 1991; 142: 343-351.
14. Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 1996; 218: 290-295.
15. Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol 1994; 63: 4241-4250.
16. Chong H, Vile RG. Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Therapy 1996; 3: 624-629.
17. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
18. Finer, MF et al. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43-50.
19. Soneoka Y et al. Transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995, 23: 628-633.
20. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996; 70: 5701-5705.
21. Forestell SP, Böhnlein E, Rigg RJ. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Therapy 1995, 2: 723-730.
22. Le Doux JM, Morgan JR, Snow RG, Yarmush ML. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996; 70: 6468-6473.
23. O'Neill RR et al. Envelope and long terminal repeat sequences of a cloned infectious NZB xenotropic murine leukemia virus. J Virol 1985; 53: 100-106.
24. Ott D, Friedrich R, Rein A. Sequence analysis of amphotropic 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses. J Virol 1990; 64: 757-766.
25. Rigg RJ et al. Detection of intracellular HTV-1 Rev protein by flow cytometry. J Immunol Meth 1995; 188: 187-195.
26. Bevec D, Dobrovnik M, Hauber J, Böhnlein E. Inhibition of human immunodeficiency virus type 1 by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci USA 1992; 89: 9870-9874.
27. Tagawa M, Nakauchi H, Herzenberg LA, Nolan GP. Formal proof that different-size Lyt-2 polypeptides arise from differential splicing and post-transcriptional regulation. Proc Natl Acad Sci USA 1986; 83: 3422-3426.
28. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of Moloney murine leukaemia virus. Nature 1981; 293: 543-548.
29. Bender MA, Palmer TD, Gelinas RE, Miller AD. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol 1987; 64: 1639-1646.
30. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression Biotechniques 1989; 7: 980-990.
31. Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
32. Yee JK et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564-9568.
33. Teich N. Taxonomy of retroviruses. In: Weiss R, Teich N, Varmus H, Coffin J (eds). RNA Tumour Viruses. Cold Spring Harbor Laboratory Press: New York, 1984, pp 25-207.
34. Wilson CA, Farrell KB, Eiden MV. Properties of a unique form of the murine amphotropic leukemia virus receptor expressed on hamster cells. J Virol 1994; 68: 7697-7703.
35. Wilson CA et al. The dual-function hamster receptor for amphotropic murine leukemia virus (MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate symporter. J Virol 1995; 69: 534-537.
36. Cullen BR, Skalka AM, Ju G. Endogenous avian retroviruses contain deficient promoter and leader sequences. Proc Natl Acad Sci USA 1983; 80: 2946-2950.
37. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-8007.
38. Muenchau DD et al. Analysis of retroviral packaging lines for generation of replication-competent retrovirus. Virology 1990; 176: 262-265.
39. Forestell SP, Dando JS, Böhnlein E, Rigg RJ. Improved detection of replication competent retrovirus. J Virol Meth 1996; 60: 171-178.
40. Printz M et al. Recombinant retroviral vector interferes with the detection of amphotropic replication-competent retrovirus in standard culture assays. Gene Therapy 1995; 2: 143-150.
41. Bestwick RK, Kozak SL, Kabat D. Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci USA 1988; 85: 5404-5408.
42. Bodine DM et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87: 3738-3742.
43. Cosset FL et al. Use of helper cells with two host ranges to generate high-titer retroviral vectors. Virology 1993; 193: 385-395.
44. Hoatlin ME, Kozak SL, Spiro C, Kabat D. Amplified and tissue directed expression of retroviral vectors using ping-pong techniques. J Mol Med 1995; 73: 113-120.
45. Plavec I et al. Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells. Gene Therapy 1996; 3: 717-724.
46. Su L et al. Hematopoietic stem cell-based gene therapy for AIDS: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood 1997; 89: 2283-2290.
47. Bonyhadi ML et al. Efficient expression of RevM10 in human hematopoietic stem cell derived T cells: a preclinical feasibility study J Virol 1997 (in press).
48. Morgan JR et al. Retrovirus infection: effect of time and target cell number. J Virol 1995; 69: 6994-7000.
49. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-266.
50. Miller AD, Buttimore C Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
51. Kotani H et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
52. Bahnson AB et al. Centrifugal enhancement of retroviral mediated gene transfer. J Virol Meth 1995; 54: 131-143
53. Sasaki DT et al. Development of a clinically acceptable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hemat 1995; 4: 503-514.